Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV DMT single ascending dose and repeat-dose study in healthy volunteers
NL-OMON51817Recruiting
- Sponsor
- Algernon Pharmaceuticals Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of DMT in stroke and Post-stroke Upper Limb Motor Impairment (4 arms), sponsored by Algernon Pharmaceuticals Inc. Started Nov 2022; status: recruiting.
02
Drugs
DMT
03
Conditions
strokePost-stroke Upper Limb Motor Impairment
Beyond the preview
Go deeper on NL-OMON51817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51817.